Papua New Guinea vs Switzerland: Prevalence of hypertension, male
Papua New Guinea
25.4%
in 2019
Switzerland
26.4%
in 2019
Papua New Guinea rank
186th
Switzerland rank
183rd
Prevalence of hypertension, male over time
- Papua New Guinea
- Switzerland
How they compare
Switzerland currently reports 26.4% against 25.4% in Papua New Guinea, a difference of 1.0%.
Across all 30 years both countries report, Switzerland has been ahead every year.
Papua New Guinea ranks 186th and Switzerland ranks 183rd of 192 countries.
Switzerland has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Papua New Guinea | Switzerland | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 21.9% | 38.4% | 16.4% | Switzerland |
| 2000s | 21.4% | 34.1% | 12.8% | Switzerland |
| 2010s | 23.9% | 28.9% | 5.0% | Switzerland |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hypertension, male, Papua New Guinea or Switzerland?
- Switzerland, at 26.4% against 25.4% in Papua New Guinea as of 2019.
- What is the difference in prevalence of hypertension, male between Papua New Guinea and Switzerland?
- 1.0%, with Switzerland ahead.
- How many years of comparable data are there for Papua New Guinea and Switzerland?
- 30 years are reported by both, from 1990 to 2019.
- How do Papua New Guinea and Switzerland rank globally for prevalence of hypertension, male?
- Papua New Guinea ranks 186th and Switzerland ranks 183rd of 192 countries.
- Where does this data come from?
- World Health Organization's Global Health Observatory Data Repository, published as Prevalence of hypertension, male (% of male adults ages 30-79). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Prevalence of hypertension, male, is the percentage of male adults ages 30-79 with hypertension (defined as having systolic blood pressure =140 mmHg, diastolic blood pressure =90 mmHg, or taking medication for hypertension). The data is age-standardized.